Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637961 · ClinicalTrials.gov registry record · Phase 2
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01637961: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01637961 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01637961, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01637961
The ClinicalTrials.gov registry entry for NCT01637961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01637961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01637961 about?
NCT01637961 is a clinical study titled "Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus". This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01637961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2012-08. Estimated completion is 2017-02-11.
What interventions are being tested in trial NCT01637961?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Alisertib (DRUG).
Who is sponsoring clinical trial NCT01637961?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.